1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Screening and Functional Validation of Genomic Variants Associated with Human Congenital Anomalies (R01 Clinical Trial Not Allowed) is sponsored by NIH Gabriella Miller Kids First Pediatric Research Program. This grant focuses on screening and functional validation of genomic variants linked to human congenital anomalies. Given the shared genetic pathways between childhood cancer and birth defects, this can be relevant to St.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Screening and Functional Validation of Genomic Variants Associated with Human Congenital Anomalies (R01 Clinical Trial Not Allowed) | Research Funding National Institutes of Health Screening and Functional Validation of Genomic Variants Associated with Human Congenital Anomalies (R01 Clinical Trial Not Allowed) Rapid advances in genotyping and next generation sequencing technologies have led to the identification of genetic variants that are associated with a wide variety of congenital defects including structural congenital anomalies (SCAs), intellectual developmental disabilities (IDDs) and inborn errors of metabolism (IEMs).
Large quantities of genomic data collected from pediatric congenital anomalies cohorts are available to the research community through several databases such as the Database of Genotypes and Phenotypes (dbGaP), the Gabriella Miller Kids First Data Resource Portal, the European Genome-Phenome Archive and Clinical Genome Resource (ClinGen).
The purpose of this initiative is to promote the screening, functional validation and characterization of congenital anomaly-associated genetic variants identified through public facing databases and individual efforts using in-silico tools, appropriate animal models, in vitro systems or multi-pronged approaches.
This initiative addresses a challenging gap between identifying sequence variations of potential interest and recognizing which of those variations have functional effects on the phenotype of interest. Funding Opportunity Goal(s): To conduct and support laboratory research, clinical trials, and studies with people that explore health processes.
NICHD researchers examine growth and development, biologic and reproductive functions, behavior patterns, and population dynamics to protect and maintain the health of all people. To examine the impact of disabilities, diseases, and defects on the lives of individuals. With this information, the NICHD hopes to restore, increase, and maximize the capabilities of people affected by disease and injury.
To sponsor training programs for scientists, doctors, and researchers to ensure that NICHD research can continue. By training these professionals in the latest research methods and technologies, the NICHD will be able to conduct its research and make health research progress until all children, adults, families, and populations enjoy good health.
The mission of the NICHD is to ensure that every person is born healthy and wanted, that women suffer no harmful effects from reproductive processes, and that all children have the chance to achieve their full potential for healthy and productive lives, free from disease or disability, and to ensure the health, productivity, independence, and well-being of all people through optimal rehabilitation.
Letter of Intent Due Date(s): 30 days prior to application due date(s) R01 Due Dates: Feb. 5, Jun. 5, Oct.
5 PAR-25-185 Expiration Date January 08, 2028 Application budgets are limited to $499,999 direct costs per year and need to reflect the actual needs of the proposed projects. The scope of the proposed project should determine the project period. The maximum project period is 5 years.
According to the current listing, eligibility includes: Investigators at academic, medical, or research institutions. Confirm the full requirements in the official notice before applying.
Screening and Functional Validation of Genomic Variants Associated with Human Congenital Anomalies (R01 Clinical Trial Not Allowed) is funded by NIH Gabriella Miller Kids First Pediatric Research Program. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Investigator Initiated Innovation in Computational Genomics and Data Science (R21 Clinical Trial Not Allowed) is sponsored by NIH Gabriella Miller Kids First Pediatric Research Program. This opportunity supports innovative computational genomics and data science research initiated by investigators, which can be highly relevant for analyzing large datasets in pediatric cancer and rare diseases.
Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed) is sponsored by NIH Gabriella Miller Kids First Pediatric Research Program. This grant supports research focused on the secondary analysis and integration of existing data to understand cancer risk and related outcomes, particularly relevant for pediatric cancer research.
Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed) is sponsored by NIH Gabriella Miller Kids First Pediatric Research Program. This grant supports exploratory and developmental research projects that involve secondary analysis and integration of existing data to elucidate cancer risk and related outcomes, with a focus on pediatric populations.
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article